Genetic Biomarkers For Antipsychotic-Induced Parkinsonism: The Challenge of Replication And Clinical Applicability
Antipsychotic-induced Parkinsonism (AIP) is an adverse effect that significantly limits the use of first generation antipsychotic drugs (FGAs). Frequency estimates vary from 10-40%. Second generation antipsychotics (SGAs) are associated with lower AIP rates but carry a significant risk of metabolic...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Lerer, Bernard [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017transfer abstract |
|---|
| Umfang: |
2 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Temperature-dependence laws of absorption line shape parameters of the CO - Wilzewski, J.S. ELSEVIER, 2017, ENP : the journal of the European College of Neuropsychopharmacology, Amsterdam |
|---|---|
| Übergeordnetes Werk: |
volume:27 ; year:2017 ; pages:366-367 ; extent:2 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.euroneuro.2016.09.391 |
|---|
| Katalog-ID: |
ELV025396250 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV025396250 | ||
| 003 | DE-627 | ||
| 005 | 20230625144710.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.euroneuro.2016.09.391 |2 doi | |
| 028 | 5 | 2 | |a GBVA2017014000005.pica |
| 035 | |a (DE-627)ELV025396250 | ||
| 035 | |a (ELSEVIER)S0924-977X(16)30587-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 150 |a 610 | |
| 082 | 0 | 4 | |a 150 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 530 |q VZ |
| 084 | |a 33.00 |2 bkl | ||
| 100 | 1 | |a Lerer, Bernard |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Genetic Biomarkers For Antipsychotic-Induced Parkinsonism: The Challenge of Replication And Clinical Applicability |
| 264 | 1 | |c 2017transfer abstract | |
| 300 | |a 2 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Antipsychotic-induced Parkinsonism (AIP) is an adverse effect that significantly limits the use of first generation antipsychotic drugs (FGAs). Frequency estimates vary from 10-40%. Second generation antipsychotics (SGAs) are associated with lower AIP rates but carry a significant risk of metabolic adverse effects. Thus, personalized treatment with antipsychotics is a key objective in pharmacogenomics. Several studies have sought genetic biomarkers for AIP. Most were retrospective and employed candidate variants in case-control association studies. Some associations have been reported but replication has not been consistent and a level of predictive power appropriate for clinical application has not been demonstrated. A case in point is the association of the functional rs4606 polymorphism in the RGS2 gene with susceptibility to early onset of AIP. This was first reported by our group in a prospective study of Israeli patients with schizophrenia (Greenbaum et al, 2007). The association was replicated in a retrospectively evaluated U.S. sample (Greenbaum et al, 2009) but not by other authors. We also obtained supporting evidence from a transgenic mouse model (Greenbaum et al, 2012a). Subsequently, we presented evidence for association of the intronic SNP, rs12678719, in the ZFPM2 gene with susceptibility to AIP. This was observed in a secondary analysis of CATIE data (Alkelai et al, 2009) and replicated in an independent U.S. case control sample (Greenbaum et al 2012b). Considering the two genetic variants together yielded a positive predictive value of 0.71 and a negative predictive value of 0.68 (odds ratio of 5.13) (Lerer et al, unpublished). To validate these findings we recruited a new sample of 404 Israeli schizophrenia patients on a stable regimen of antipsychotic treatment, of whom 383 had valid phenotypic and genetic data and were included in the data analysis (AIP positive: Simpson Angus Scale (SAS) score>0.3, N=206; AIP resistant, SAS ≤0.13, N=177). Recruitment was constrained to insure equivalent proportions of patients on FGAs and SGAs. Taking into account confounding variables such as age, gender, age at first antipsychotic treatment, ethnicity, antipsychotic drug dose in chlorpromazine units and treatment with anticholinergic medication, the results of this study showed no significant contribution of rs4606 in RGS2 and rs12678719 in ZFPM2 to AIP susceptibility. This was also the case when examining a more extreme phenotype. These findings ill... | ||
| 520 | |a Antipsychotic-induced Parkinsonism (AIP) is an adverse effect that significantly limits the use of first generation antipsychotic drugs (FGAs). Frequency estimates vary from 10-40%. Second generation antipsychotics (SGAs) are associated with lower AIP rates but carry a significant risk of metabolic adverse effects. Thus, personalized treatment with antipsychotics is a key objective in pharmacogenomics. Several studies have sought genetic biomarkers for AIP. Most were retrospective and employed candidate variants in case-control association studies. Some associations have been reported but replication has not been consistent and a level of predictive power appropriate for clinical application has not been demonstrated. A case in point is the association of the functional rs4606 polymorphism in the RGS2 gene with susceptibility to early onset of AIP. This was first reported by our group in a prospective study of Israeli patients with schizophrenia (Greenbaum et al, 2007). The association was replicated in a retrospectively evaluated U.S. sample (Greenbaum et al, 2009) but not by other authors. We also obtained supporting evidence from a transgenic mouse model (Greenbaum et al, 2012a). Subsequently, we presented evidence for association of the intronic SNP, rs12678719, in the ZFPM2 gene with susceptibility to AIP. This was observed in a secondary analysis of CATIE data (Alkelai et al, 2009) and replicated in an independent U.S. case control sample (Greenbaum et al 2012b). Considering the two genetic variants together yielded a positive predictive value of 0.71 and a negative predictive value of 0.68 (odds ratio of 5.13) (Lerer et al, unpublished). To validate these findings we recruited a new sample of 404 Israeli schizophrenia patients on a stable regimen of antipsychotic treatment, of whom 383 had valid phenotypic and genetic data and were included in the data analysis (AIP positive: Simpson Angus Scale (SAS) score>0.3, N=206; AIP resistant, SAS ≤0.13, N=177). Recruitment was constrained to insure equivalent proportions of patients on FGAs and SGAs. Taking into account confounding variables such as age, gender, age at first antipsychotic treatment, ethnicity, antipsychotic drug dose in chlorpromazine units and treatment with anticholinergic medication, the results of this study showed no significant contribution of rs4606 in RGS2 and rs12678719 in ZFPM2 to AIP susceptibility. This was also the case when examining a more extreme phenotype. These findings ill... | ||
| 700 | 1 | |a Greenbaum, Lior |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Wilzewski, J.S. ELSEVIER |t Temperature-dependence laws of absorption line shape parameters of the CO |d 2017 |d ENP : the journal of the European College of Neuropsychopharmacology |g Amsterdam |w (DE-627)ELV000200816 |
| 773 | 1 | 8 | |g volume:27 |g year:2017 |g pages:366-367 |g extent:2 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.euroneuro.2016.09.391 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 33.00 |j Physik: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 27 |j 2017 |h 366-367 |g 2 |y 27.2017, S366-, (2 S.) | ||
| 953 | |2 045F |a 150 | ||
| author_variant |
b l bl |
|---|---|
| matchkey_str |
lererbernardgreenbaumlior:2017----:eeiboakrfrniscoiidcdaknoimhcalnefelct |
| hierarchy_sort_str |
2017transfer abstract |
| bklnumber |
33.00 |
| publishDate |
2017 |
| allfields |
10.1016/j.euroneuro.2016.09.391 doi GBVA2017014000005.pica (DE-627)ELV025396250 (ELSEVIER)S0924-977X(16)30587-9 DE-627 ger DE-627 rakwb eng 150 610 150 DE-600 610 DE-600 530 VZ 33.00 bkl Lerer, Bernard verfasserin aut Genetic Biomarkers For Antipsychotic-Induced Parkinsonism: The Challenge of Replication And Clinical Applicability 2017transfer abstract 2 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Antipsychotic-induced Parkinsonism (AIP) is an adverse effect that significantly limits the use of first generation antipsychotic drugs (FGAs). Frequency estimates vary from 10-40%. Second generation antipsychotics (SGAs) are associated with lower AIP rates but carry a significant risk of metabolic adverse effects. Thus, personalized treatment with antipsychotics is a key objective in pharmacogenomics. Several studies have sought genetic biomarkers for AIP. Most were retrospective and employed candidate variants in case-control association studies. Some associations have been reported but replication has not been consistent and a level of predictive power appropriate for clinical application has not been demonstrated. A case in point is the association of the functional rs4606 polymorphism in the RGS2 gene with susceptibility to early onset of AIP. This was first reported by our group in a prospective study of Israeli patients with schizophrenia (Greenbaum et al, 2007). The association was replicated in a retrospectively evaluated U.S. sample (Greenbaum et al, 2009) but not by other authors. We also obtained supporting evidence from a transgenic mouse model (Greenbaum et al, 2012a). Subsequently, we presented evidence for association of the intronic SNP, rs12678719, in the ZFPM2 gene with susceptibility to AIP. This was observed in a secondary analysis of CATIE data (Alkelai et al, 2009) and replicated in an independent U.S. case control sample (Greenbaum et al 2012b). Considering the two genetic variants together yielded a positive predictive value of 0.71 and a negative predictive value of 0.68 (odds ratio of 5.13) (Lerer et al, unpublished). To validate these findings we recruited a new sample of 404 Israeli schizophrenia patients on a stable regimen of antipsychotic treatment, of whom 383 had valid phenotypic and genetic data and were included in the data analysis (AIP positive: Simpson Angus Scale (SAS) score>0.3, N=206; AIP resistant, SAS ≤0.13, N=177). Recruitment was constrained to insure equivalent proportions of patients on FGAs and SGAs. Taking into account confounding variables such as age, gender, age at first antipsychotic treatment, ethnicity, antipsychotic drug dose in chlorpromazine units and treatment with anticholinergic medication, the results of this study showed no significant contribution of rs4606 in RGS2 and rs12678719 in ZFPM2 to AIP susceptibility. This was also the case when examining a more extreme phenotype. These findings ill... Antipsychotic-induced Parkinsonism (AIP) is an adverse effect that significantly limits the use of first generation antipsychotic drugs (FGAs). Frequency estimates vary from 10-40%. Second generation antipsychotics (SGAs) are associated with lower AIP rates but carry a significant risk of metabolic adverse effects. Thus, personalized treatment with antipsychotics is a key objective in pharmacogenomics. Several studies have sought genetic biomarkers for AIP. Most were retrospective and employed candidate variants in case-control association studies. Some associations have been reported but replication has not been consistent and a level of predictive power appropriate for clinical application has not been demonstrated. A case in point is the association of the functional rs4606 polymorphism in the RGS2 gene with susceptibility to early onset of AIP. This was first reported by our group in a prospective study of Israeli patients with schizophrenia (Greenbaum et al, 2007). The association was replicated in a retrospectively evaluated U.S. sample (Greenbaum et al, 2009) but not by other authors. We also obtained supporting evidence from a transgenic mouse model (Greenbaum et al, 2012a). Subsequently, we presented evidence for association of the intronic SNP, rs12678719, in the ZFPM2 gene with susceptibility to AIP. This was observed in a secondary analysis of CATIE data (Alkelai et al, 2009) and replicated in an independent U.S. case control sample (Greenbaum et al 2012b). Considering the two genetic variants together yielded a positive predictive value of 0.71 and a negative predictive value of 0.68 (odds ratio of 5.13) (Lerer et al, unpublished). To validate these findings we recruited a new sample of 404 Israeli schizophrenia patients on a stable regimen of antipsychotic treatment, of whom 383 had valid phenotypic and genetic data and were included in the data analysis (AIP positive: Simpson Angus Scale (SAS) score>0.3, N=206; AIP resistant, SAS ≤0.13, N=177). Recruitment was constrained to insure equivalent proportions of patients on FGAs and SGAs. Taking into account confounding variables such as age, gender, age at first antipsychotic treatment, ethnicity, antipsychotic drug dose in chlorpromazine units and treatment with anticholinergic medication, the results of this study showed no significant contribution of rs4606 in RGS2 and rs12678719 in ZFPM2 to AIP susceptibility. This was also the case when examining a more extreme phenotype. These findings ill... Greenbaum, Lior oth Enthalten in Elsevier Wilzewski, J.S. ELSEVIER Temperature-dependence laws of absorption line shape parameters of the CO 2017 ENP : the journal of the European College of Neuropsychopharmacology Amsterdam (DE-627)ELV000200816 volume:27 year:2017 pages:366-367 extent:2 https://doi.org/10.1016/j.euroneuro.2016.09.391 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 33.00 Physik: Allgemeines VZ AR 27 2017 366-367 2 27.2017, S366-, (2 S.) 045F 150 |
| spelling |
10.1016/j.euroneuro.2016.09.391 doi GBVA2017014000005.pica (DE-627)ELV025396250 (ELSEVIER)S0924-977X(16)30587-9 DE-627 ger DE-627 rakwb eng 150 610 150 DE-600 610 DE-600 530 VZ 33.00 bkl Lerer, Bernard verfasserin aut Genetic Biomarkers For Antipsychotic-Induced Parkinsonism: The Challenge of Replication And Clinical Applicability 2017transfer abstract 2 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Antipsychotic-induced Parkinsonism (AIP) is an adverse effect that significantly limits the use of first generation antipsychotic drugs (FGAs). Frequency estimates vary from 10-40%. Second generation antipsychotics (SGAs) are associated with lower AIP rates but carry a significant risk of metabolic adverse effects. Thus, personalized treatment with antipsychotics is a key objective in pharmacogenomics. Several studies have sought genetic biomarkers for AIP. Most were retrospective and employed candidate variants in case-control association studies. Some associations have been reported but replication has not been consistent and a level of predictive power appropriate for clinical application has not been demonstrated. A case in point is the association of the functional rs4606 polymorphism in the RGS2 gene with susceptibility to early onset of AIP. This was first reported by our group in a prospective study of Israeli patients with schizophrenia (Greenbaum et al, 2007). The association was replicated in a retrospectively evaluated U.S. sample (Greenbaum et al, 2009) but not by other authors. We also obtained supporting evidence from a transgenic mouse model (Greenbaum et al, 2012a). Subsequently, we presented evidence for association of the intronic SNP, rs12678719, in the ZFPM2 gene with susceptibility to AIP. This was observed in a secondary analysis of CATIE data (Alkelai et al, 2009) and replicated in an independent U.S. case control sample (Greenbaum et al 2012b). Considering the two genetic variants together yielded a positive predictive value of 0.71 and a negative predictive value of 0.68 (odds ratio of 5.13) (Lerer et al, unpublished). To validate these findings we recruited a new sample of 404 Israeli schizophrenia patients on a stable regimen of antipsychotic treatment, of whom 383 had valid phenotypic and genetic data and were included in the data analysis (AIP positive: Simpson Angus Scale (SAS) score>0.3, N=206; AIP resistant, SAS ≤0.13, N=177). Recruitment was constrained to insure equivalent proportions of patients on FGAs and SGAs. Taking into account confounding variables such as age, gender, age at first antipsychotic treatment, ethnicity, antipsychotic drug dose in chlorpromazine units and treatment with anticholinergic medication, the results of this study showed no significant contribution of rs4606 in RGS2 and rs12678719 in ZFPM2 to AIP susceptibility. This was also the case when examining a more extreme phenotype. These findings ill... Antipsychotic-induced Parkinsonism (AIP) is an adverse effect that significantly limits the use of first generation antipsychotic drugs (FGAs). Frequency estimates vary from 10-40%. Second generation antipsychotics (SGAs) are associated with lower AIP rates but carry a significant risk of metabolic adverse effects. Thus, personalized treatment with antipsychotics is a key objective in pharmacogenomics. Several studies have sought genetic biomarkers for AIP. Most were retrospective and employed candidate variants in case-control association studies. Some associations have been reported but replication has not been consistent and a level of predictive power appropriate for clinical application has not been demonstrated. A case in point is the association of the functional rs4606 polymorphism in the RGS2 gene with susceptibility to early onset of AIP. This was first reported by our group in a prospective study of Israeli patients with schizophrenia (Greenbaum et al, 2007). The association was replicated in a retrospectively evaluated U.S. sample (Greenbaum et al, 2009) but not by other authors. We also obtained supporting evidence from a transgenic mouse model (Greenbaum et al, 2012a). Subsequently, we presented evidence for association of the intronic SNP, rs12678719, in the ZFPM2 gene with susceptibility to AIP. This was observed in a secondary analysis of CATIE data (Alkelai et al, 2009) and replicated in an independent U.S. case control sample (Greenbaum et al 2012b). Considering the two genetic variants together yielded a positive predictive value of 0.71 and a negative predictive value of 0.68 (odds ratio of 5.13) (Lerer et al, unpublished). To validate these findings we recruited a new sample of 404 Israeli schizophrenia patients on a stable regimen of antipsychotic treatment, of whom 383 had valid phenotypic and genetic data and were included in the data analysis (AIP positive: Simpson Angus Scale (SAS) score>0.3, N=206; AIP resistant, SAS ≤0.13, N=177). Recruitment was constrained to insure equivalent proportions of patients on FGAs and SGAs. Taking into account confounding variables such as age, gender, age at first antipsychotic treatment, ethnicity, antipsychotic drug dose in chlorpromazine units and treatment with anticholinergic medication, the results of this study showed no significant contribution of rs4606 in RGS2 and rs12678719 in ZFPM2 to AIP susceptibility. This was also the case when examining a more extreme phenotype. These findings ill... Greenbaum, Lior oth Enthalten in Elsevier Wilzewski, J.S. ELSEVIER Temperature-dependence laws of absorption line shape parameters of the CO 2017 ENP : the journal of the European College of Neuropsychopharmacology Amsterdam (DE-627)ELV000200816 volume:27 year:2017 pages:366-367 extent:2 https://doi.org/10.1016/j.euroneuro.2016.09.391 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 33.00 Physik: Allgemeines VZ AR 27 2017 366-367 2 27.2017, S366-, (2 S.) 045F 150 |
| allfields_unstemmed |
10.1016/j.euroneuro.2016.09.391 doi GBVA2017014000005.pica (DE-627)ELV025396250 (ELSEVIER)S0924-977X(16)30587-9 DE-627 ger DE-627 rakwb eng 150 610 150 DE-600 610 DE-600 530 VZ 33.00 bkl Lerer, Bernard verfasserin aut Genetic Biomarkers For Antipsychotic-Induced Parkinsonism: The Challenge of Replication And Clinical Applicability 2017transfer abstract 2 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Antipsychotic-induced Parkinsonism (AIP) is an adverse effect that significantly limits the use of first generation antipsychotic drugs (FGAs). Frequency estimates vary from 10-40%. Second generation antipsychotics (SGAs) are associated with lower AIP rates but carry a significant risk of metabolic adverse effects. Thus, personalized treatment with antipsychotics is a key objective in pharmacogenomics. Several studies have sought genetic biomarkers for AIP. Most were retrospective and employed candidate variants in case-control association studies. Some associations have been reported but replication has not been consistent and a level of predictive power appropriate for clinical application has not been demonstrated. A case in point is the association of the functional rs4606 polymorphism in the RGS2 gene with susceptibility to early onset of AIP. This was first reported by our group in a prospective study of Israeli patients with schizophrenia (Greenbaum et al, 2007). The association was replicated in a retrospectively evaluated U.S. sample (Greenbaum et al, 2009) but not by other authors. We also obtained supporting evidence from a transgenic mouse model (Greenbaum et al, 2012a). Subsequently, we presented evidence for association of the intronic SNP, rs12678719, in the ZFPM2 gene with susceptibility to AIP. This was observed in a secondary analysis of CATIE data (Alkelai et al, 2009) and replicated in an independent U.S. case control sample (Greenbaum et al 2012b). Considering the two genetic variants together yielded a positive predictive value of 0.71 and a negative predictive value of 0.68 (odds ratio of 5.13) (Lerer et al, unpublished). To validate these findings we recruited a new sample of 404 Israeli schizophrenia patients on a stable regimen of antipsychotic treatment, of whom 383 had valid phenotypic and genetic data and were included in the data analysis (AIP positive: Simpson Angus Scale (SAS) score>0.3, N=206; AIP resistant, SAS ≤0.13, N=177). Recruitment was constrained to insure equivalent proportions of patients on FGAs and SGAs. Taking into account confounding variables such as age, gender, age at first antipsychotic treatment, ethnicity, antipsychotic drug dose in chlorpromazine units and treatment with anticholinergic medication, the results of this study showed no significant contribution of rs4606 in RGS2 and rs12678719 in ZFPM2 to AIP susceptibility. This was also the case when examining a more extreme phenotype. These findings ill... Antipsychotic-induced Parkinsonism (AIP) is an adverse effect that significantly limits the use of first generation antipsychotic drugs (FGAs). Frequency estimates vary from 10-40%. Second generation antipsychotics (SGAs) are associated with lower AIP rates but carry a significant risk of metabolic adverse effects. Thus, personalized treatment with antipsychotics is a key objective in pharmacogenomics. Several studies have sought genetic biomarkers for AIP. Most were retrospective and employed candidate variants in case-control association studies. Some associations have been reported but replication has not been consistent and a level of predictive power appropriate for clinical application has not been demonstrated. A case in point is the association of the functional rs4606 polymorphism in the RGS2 gene with susceptibility to early onset of AIP. This was first reported by our group in a prospective study of Israeli patients with schizophrenia (Greenbaum et al, 2007). The association was replicated in a retrospectively evaluated U.S. sample (Greenbaum et al, 2009) but not by other authors. We also obtained supporting evidence from a transgenic mouse model (Greenbaum et al, 2012a). Subsequently, we presented evidence for association of the intronic SNP, rs12678719, in the ZFPM2 gene with susceptibility to AIP. This was observed in a secondary analysis of CATIE data (Alkelai et al, 2009) and replicated in an independent U.S. case control sample (Greenbaum et al 2012b). Considering the two genetic variants together yielded a positive predictive value of 0.71 and a negative predictive value of 0.68 (odds ratio of 5.13) (Lerer et al, unpublished). To validate these findings we recruited a new sample of 404 Israeli schizophrenia patients on a stable regimen of antipsychotic treatment, of whom 383 had valid phenotypic and genetic data and were included in the data analysis (AIP positive: Simpson Angus Scale (SAS) score>0.3, N=206; AIP resistant, SAS ≤0.13, N=177). Recruitment was constrained to insure equivalent proportions of patients on FGAs and SGAs. Taking into account confounding variables such as age, gender, age at first antipsychotic treatment, ethnicity, antipsychotic drug dose in chlorpromazine units and treatment with anticholinergic medication, the results of this study showed no significant contribution of rs4606 in RGS2 and rs12678719 in ZFPM2 to AIP susceptibility. This was also the case when examining a more extreme phenotype. These findings ill... Greenbaum, Lior oth Enthalten in Elsevier Wilzewski, J.S. ELSEVIER Temperature-dependence laws of absorption line shape parameters of the CO 2017 ENP : the journal of the European College of Neuropsychopharmacology Amsterdam (DE-627)ELV000200816 volume:27 year:2017 pages:366-367 extent:2 https://doi.org/10.1016/j.euroneuro.2016.09.391 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 33.00 Physik: Allgemeines VZ AR 27 2017 366-367 2 27.2017, S366-, (2 S.) 045F 150 |
| allfieldsGer |
10.1016/j.euroneuro.2016.09.391 doi GBVA2017014000005.pica (DE-627)ELV025396250 (ELSEVIER)S0924-977X(16)30587-9 DE-627 ger DE-627 rakwb eng 150 610 150 DE-600 610 DE-600 530 VZ 33.00 bkl Lerer, Bernard verfasserin aut Genetic Biomarkers For Antipsychotic-Induced Parkinsonism: The Challenge of Replication And Clinical Applicability 2017transfer abstract 2 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Antipsychotic-induced Parkinsonism (AIP) is an adverse effect that significantly limits the use of first generation antipsychotic drugs (FGAs). Frequency estimates vary from 10-40%. Second generation antipsychotics (SGAs) are associated with lower AIP rates but carry a significant risk of metabolic adverse effects. Thus, personalized treatment with antipsychotics is a key objective in pharmacogenomics. Several studies have sought genetic biomarkers for AIP. Most were retrospective and employed candidate variants in case-control association studies. Some associations have been reported but replication has not been consistent and a level of predictive power appropriate for clinical application has not been demonstrated. A case in point is the association of the functional rs4606 polymorphism in the RGS2 gene with susceptibility to early onset of AIP. This was first reported by our group in a prospective study of Israeli patients with schizophrenia (Greenbaum et al, 2007). The association was replicated in a retrospectively evaluated U.S. sample (Greenbaum et al, 2009) but not by other authors. We also obtained supporting evidence from a transgenic mouse model (Greenbaum et al, 2012a). Subsequently, we presented evidence for association of the intronic SNP, rs12678719, in the ZFPM2 gene with susceptibility to AIP. This was observed in a secondary analysis of CATIE data (Alkelai et al, 2009) and replicated in an independent U.S. case control sample (Greenbaum et al 2012b). Considering the two genetic variants together yielded a positive predictive value of 0.71 and a negative predictive value of 0.68 (odds ratio of 5.13) (Lerer et al, unpublished). To validate these findings we recruited a new sample of 404 Israeli schizophrenia patients on a stable regimen of antipsychotic treatment, of whom 383 had valid phenotypic and genetic data and were included in the data analysis (AIP positive: Simpson Angus Scale (SAS) score>0.3, N=206; AIP resistant, SAS ≤0.13, N=177). Recruitment was constrained to insure equivalent proportions of patients on FGAs and SGAs. Taking into account confounding variables such as age, gender, age at first antipsychotic treatment, ethnicity, antipsychotic drug dose in chlorpromazine units and treatment with anticholinergic medication, the results of this study showed no significant contribution of rs4606 in RGS2 and rs12678719 in ZFPM2 to AIP susceptibility. This was also the case when examining a more extreme phenotype. These findings ill... Antipsychotic-induced Parkinsonism (AIP) is an adverse effect that significantly limits the use of first generation antipsychotic drugs (FGAs). Frequency estimates vary from 10-40%. Second generation antipsychotics (SGAs) are associated with lower AIP rates but carry a significant risk of metabolic adverse effects. Thus, personalized treatment with antipsychotics is a key objective in pharmacogenomics. Several studies have sought genetic biomarkers for AIP. Most were retrospective and employed candidate variants in case-control association studies. Some associations have been reported but replication has not been consistent and a level of predictive power appropriate for clinical application has not been demonstrated. A case in point is the association of the functional rs4606 polymorphism in the RGS2 gene with susceptibility to early onset of AIP. This was first reported by our group in a prospective study of Israeli patients with schizophrenia (Greenbaum et al, 2007). The association was replicated in a retrospectively evaluated U.S. sample (Greenbaum et al, 2009) but not by other authors. We also obtained supporting evidence from a transgenic mouse model (Greenbaum et al, 2012a). Subsequently, we presented evidence for association of the intronic SNP, rs12678719, in the ZFPM2 gene with susceptibility to AIP. This was observed in a secondary analysis of CATIE data (Alkelai et al, 2009) and replicated in an independent U.S. case control sample (Greenbaum et al 2012b). Considering the two genetic variants together yielded a positive predictive value of 0.71 and a negative predictive value of 0.68 (odds ratio of 5.13) (Lerer et al, unpublished). To validate these findings we recruited a new sample of 404 Israeli schizophrenia patients on a stable regimen of antipsychotic treatment, of whom 383 had valid phenotypic and genetic data and were included in the data analysis (AIP positive: Simpson Angus Scale (SAS) score>0.3, N=206; AIP resistant, SAS ≤0.13, N=177). Recruitment was constrained to insure equivalent proportions of patients on FGAs and SGAs. Taking into account confounding variables such as age, gender, age at first antipsychotic treatment, ethnicity, antipsychotic drug dose in chlorpromazine units and treatment with anticholinergic medication, the results of this study showed no significant contribution of rs4606 in RGS2 and rs12678719 in ZFPM2 to AIP susceptibility. This was also the case when examining a more extreme phenotype. These findings ill... Greenbaum, Lior oth Enthalten in Elsevier Wilzewski, J.S. ELSEVIER Temperature-dependence laws of absorption line shape parameters of the CO 2017 ENP : the journal of the European College of Neuropsychopharmacology Amsterdam (DE-627)ELV000200816 volume:27 year:2017 pages:366-367 extent:2 https://doi.org/10.1016/j.euroneuro.2016.09.391 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 33.00 Physik: Allgemeines VZ AR 27 2017 366-367 2 27.2017, S366-, (2 S.) 045F 150 |
| allfieldsSound |
10.1016/j.euroneuro.2016.09.391 doi GBVA2017014000005.pica (DE-627)ELV025396250 (ELSEVIER)S0924-977X(16)30587-9 DE-627 ger DE-627 rakwb eng 150 610 150 DE-600 610 DE-600 530 VZ 33.00 bkl Lerer, Bernard verfasserin aut Genetic Biomarkers For Antipsychotic-Induced Parkinsonism: The Challenge of Replication And Clinical Applicability 2017transfer abstract 2 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Antipsychotic-induced Parkinsonism (AIP) is an adverse effect that significantly limits the use of first generation antipsychotic drugs (FGAs). Frequency estimates vary from 10-40%. Second generation antipsychotics (SGAs) are associated with lower AIP rates but carry a significant risk of metabolic adverse effects. Thus, personalized treatment with antipsychotics is a key objective in pharmacogenomics. Several studies have sought genetic biomarkers for AIP. Most were retrospective and employed candidate variants in case-control association studies. Some associations have been reported but replication has not been consistent and a level of predictive power appropriate for clinical application has not been demonstrated. A case in point is the association of the functional rs4606 polymorphism in the RGS2 gene with susceptibility to early onset of AIP. This was first reported by our group in a prospective study of Israeli patients with schizophrenia (Greenbaum et al, 2007). The association was replicated in a retrospectively evaluated U.S. sample (Greenbaum et al, 2009) but not by other authors. We also obtained supporting evidence from a transgenic mouse model (Greenbaum et al, 2012a). Subsequently, we presented evidence for association of the intronic SNP, rs12678719, in the ZFPM2 gene with susceptibility to AIP. This was observed in a secondary analysis of CATIE data (Alkelai et al, 2009) and replicated in an independent U.S. case control sample (Greenbaum et al 2012b). Considering the two genetic variants together yielded a positive predictive value of 0.71 and a negative predictive value of 0.68 (odds ratio of 5.13) (Lerer et al, unpublished). To validate these findings we recruited a new sample of 404 Israeli schizophrenia patients on a stable regimen of antipsychotic treatment, of whom 383 had valid phenotypic and genetic data and were included in the data analysis (AIP positive: Simpson Angus Scale (SAS) score>0.3, N=206; AIP resistant, SAS ≤0.13, N=177). Recruitment was constrained to insure equivalent proportions of patients on FGAs and SGAs. Taking into account confounding variables such as age, gender, age at first antipsychotic treatment, ethnicity, antipsychotic drug dose in chlorpromazine units and treatment with anticholinergic medication, the results of this study showed no significant contribution of rs4606 in RGS2 and rs12678719 in ZFPM2 to AIP susceptibility. This was also the case when examining a more extreme phenotype. These findings ill... Antipsychotic-induced Parkinsonism (AIP) is an adverse effect that significantly limits the use of first generation antipsychotic drugs (FGAs). Frequency estimates vary from 10-40%. Second generation antipsychotics (SGAs) are associated with lower AIP rates but carry a significant risk of metabolic adverse effects. Thus, personalized treatment with antipsychotics is a key objective in pharmacogenomics. Several studies have sought genetic biomarkers for AIP. Most were retrospective and employed candidate variants in case-control association studies. Some associations have been reported but replication has not been consistent and a level of predictive power appropriate for clinical application has not been demonstrated. A case in point is the association of the functional rs4606 polymorphism in the RGS2 gene with susceptibility to early onset of AIP. This was first reported by our group in a prospective study of Israeli patients with schizophrenia (Greenbaum et al, 2007). The association was replicated in a retrospectively evaluated U.S. sample (Greenbaum et al, 2009) but not by other authors. We also obtained supporting evidence from a transgenic mouse model (Greenbaum et al, 2012a). Subsequently, we presented evidence for association of the intronic SNP, rs12678719, in the ZFPM2 gene with susceptibility to AIP. This was observed in a secondary analysis of CATIE data (Alkelai et al, 2009) and replicated in an independent U.S. case control sample (Greenbaum et al 2012b). Considering the two genetic variants together yielded a positive predictive value of 0.71 and a negative predictive value of 0.68 (odds ratio of 5.13) (Lerer et al, unpublished). To validate these findings we recruited a new sample of 404 Israeli schizophrenia patients on a stable regimen of antipsychotic treatment, of whom 383 had valid phenotypic and genetic data and were included in the data analysis (AIP positive: Simpson Angus Scale (SAS) score>0.3, N=206; AIP resistant, SAS ≤0.13, N=177). Recruitment was constrained to insure equivalent proportions of patients on FGAs and SGAs. Taking into account confounding variables such as age, gender, age at first antipsychotic treatment, ethnicity, antipsychotic drug dose in chlorpromazine units and treatment with anticholinergic medication, the results of this study showed no significant contribution of rs4606 in RGS2 and rs12678719 in ZFPM2 to AIP susceptibility. This was also the case when examining a more extreme phenotype. These findings ill... Greenbaum, Lior oth Enthalten in Elsevier Wilzewski, J.S. ELSEVIER Temperature-dependence laws of absorption line shape parameters of the CO 2017 ENP : the journal of the European College of Neuropsychopharmacology Amsterdam (DE-627)ELV000200816 volume:27 year:2017 pages:366-367 extent:2 https://doi.org/10.1016/j.euroneuro.2016.09.391 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 33.00 Physik: Allgemeines VZ AR 27 2017 366-367 2 27.2017, S366-, (2 S.) 045F 150 |
| language |
English |
| source |
Enthalten in Temperature-dependence laws of absorption line shape parameters of the CO Amsterdam volume:27 year:2017 pages:366-367 extent:2 |
| sourceStr |
Enthalten in Temperature-dependence laws of absorption line shape parameters of the CO Amsterdam volume:27 year:2017 pages:366-367 extent:2 |
| format_phy_str_mv |
Article |
| bklname |
Physik: Allgemeines |
| institution |
findex.gbv.de |
| dewey-raw |
150 |
| isfreeaccess_bool |
false |
| container_title |
Temperature-dependence laws of absorption line shape parameters of the CO |
| authorswithroles_txt_mv |
Lerer, Bernard @@aut@@ Greenbaum, Lior @@oth@@ |
| publishDateDaySort_date |
2017-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000200816 |
| dewey-sort |
3150 |
| id |
ELV025396250 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV025396250</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625144710.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.euroneuro.2016.09.391</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017014000005.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV025396250</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0924-977X(16)30587-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">150</subfield><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">150</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">530</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">33.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Lerer, Bernard</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Genetic Biomarkers For Antipsychotic-Induced Parkinsonism: The Challenge of Replication And Clinical Applicability</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">2</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Antipsychotic-induced Parkinsonism (AIP) is an adverse effect that significantly limits the use of first generation antipsychotic drugs (FGAs). Frequency estimates vary from 10-40%. Second generation antipsychotics (SGAs) are associated with lower AIP rates but carry a significant risk of metabolic adverse effects. Thus, personalized treatment with antipsychotics is a key objective in pharmacogenomics. Several studies have sought genetic biomarkers for AIP. Most were retrospective and employed candidate variants in case-control association studies. Some associations have been reported but replication has not been consistent and a level of predictive power appropriate for clinical application has not been demonstrated. A case in point is the association of the functional rs4606 polymorphism in the RGS2 gene with susceptibility to early onset of AIP. This was first reported by our group in a prospective study of Israeli patients with schizophrenia (Greenbaum et al, 2007). The association was replicated in a retrospectively evaluated U.S. sample (Greenbaum et al, 2009) but not by other authors. We also obtained supporting evidence from a transgenic mouse model (Greenbaum et al, 2012a). Subsequently, we presented evidence for association of the intronic SNP, rs12678719, in the ZFPM2 gene with susceptibility to AIP. This was observed in a secondary analysis of CATIE data (Alkelai et al, 2009) and replicated in an independent U.S. case control sample (Greenbaum et al 2012b). Considering the two genetic variants together yielded a positive predictive value of 0.71 and a negative predictive value of 0.68 (odds ratio of 5.13) (Lerer et al, unpublished). To validate these findings we recruited a new sample of 404 Israeli schizophrenia patients on a stable regimen of antipsychotic treatment, of whom 383 had valid phenotypic and genetic data and were included in the data analysis (AIP positive: Simpson Angus Scale (SAS) score>0.3, N=206; AIP resistant, SAS ≤0.13, N=177). Recruitment was constrained to insure equivalent proportions of patients on FGAs and SGAs. Taking into account confounding variables such as age, gender, age at first antipsychotic treatment, ethnicity, antipsychotic drug dose in chlorpromazine units and treatment with anticholinergic medication, the results of this study showed no significant contribution of rs4606 in RGS2 and rs12678719 in ZFPM2 to AIP susceptibility. This was also the case when examining a more extreme phenotype. These findings ill...</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Antipsychotic-induced Parkinsonism (AIP) is an adverse effect that significantly limits the use of first generation antipsychotic drugs (FGAs). Frequency estimates vary from 10-40%. Second generation antipsychotics (SGAs) are associated with lower AIP rates but carry a significant risk of metabolic adverse effects. Thus, personalized treatment with antipsychotics is a key objective in pharmacogenomics. Several studies have sought genetic biomarkers for AIP. Most were retrospective and employed candidate variants in case-control association studies. Some associations have been reported but replication has not been consistent and a level of predictive power appropriate for clinical application has not been demonstrated. A case in point is the association of the functional rs4606 polymorphism in the RGS2 gene with susceptibility to early onset of AIP. This was first reported by our group in a prospective study of Israeli patients with schizophrenia (Greenbaum et al, 2007). The association was replicated in a retrospectively evaluated U.S. sample (Greenbaum et al, 2009) but not by other authors. We also obtained supporting evidence from a transgenic mouse model (Greenbaum et al, 2012a). Subsequently, we presented evidence for association of the intronic SNP, rs12678719, in the ZFPM2 gene with susceptibility to AIP. This was observed in a secondary analysis of CATIE data (Alkelai et al, 2009) and replicated in an independent U.S. case control sample (Greenbaum et al 2012b). Considering the two genetic variants together yielded a positive predictive value of 0.71 and a negative predictive value of 0.68 (odds ratio of 5.13) (Lerer et al, unpublished). To validate these findings we recruited a new sample of 404 Israeli schizophrenia patients on a stable regimen of antipsychotic treatment, of whom 383 had valid phenotypic and genetic data and were included in the data analysis (AIP positive: Simpson Angus Scale (SAS) score>0.3, N=206; AIP resistant, SAS ≤0.13, N=177). Recruitment was constrained to insure equivalent proportions of patients on FGAs and SGAs. Taking into account confounding variables such as age, gender, age at first antipsychotic treatment, ethnicity, antipsychotic drug dose in chlorpromazine units and treatment with anticholinergic medication, the results of this study showed no significant contribution of rs4606 in RGS2 and rs12678719 in ZFPM2 to AIP susceptibility. This was also the case when examining a more extreme phenotype. These findings ill...</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Greenbaum, Lior</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Wilzewski, J.S. ELSEVIER</subfield><subfield code="t">Temperature-dependence laws of absorption line shape parameters of the CO</subfield><subfield code="d">2017</subfield><subfield code="d">ENP : the journal of the European College of Neuropsychopharmacology</subfield><subfield code="g">Amsterdam</subfield><subfield code="w">(DE-627)ELV000200816</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:27</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:366-367</subfield><subfield code="g">extent:2</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.euroneuro.2016.09.391</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">33.00</subfield><subfield code="j">Physik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">27</subfield><subfield code="j">2017</subfield><subfield code="h">366-367</subfield><subfield code="g">2</subfield><subfield code="y">27.2017, S366-, (2 S.)</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">150</subfield></datafield></record></collection>
|
| author |
Lerer, Bernard |
| spellingShingle |
Lerer, Bernard ddc 150 ddc 610 ddc 530 bkl 33.00 Genetic Biomarkers For Antipsychotic-Induced Parkinsonism: The Challenge of Replication And Clinical Applicability |
| authorStr |
Lerer, Bernard |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000200816 |
| format |
electronic Article |
| dewey-ones |
150 - Psychology 610 - Medicine & health 530 - Physics |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
150 610 150 DE-600 610 DE-600 530 VZ 33.00 bkl Genetic Biomarkers For Antipsychotic-Induced Parkinsonism: The Challenge of Replication And Clinical Applicability |
| topic |
ddc 150 ddc 610 ddc 530 bkl 33.00 |
| topic_unstemmed |
ddc 150 ddc 610 ddc 530 bkl 33.00 |
| topic_browse |
ddc 150 ddc 610 ddc 530 bkl 33.00 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
l g lg |
| hierarchy_parent_title |
Temperature-dependence laws of absorption line shape parameters of the CO |
| hierarchy_parent_id |
ELV000200816 |
| dewey-tens |
150 - Psychology 610 - Medicine & health 530 - Physics |
| hierarchy_top_title |
Temperature-dependence laws of absorption line shape parameters of the CO |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000200816 |
| title |
Genetic Biomarkers For Antipsychotic-Induced Parkinsonism: The Challenge of Replication And Clinical Applicability |
| ctrlnum |
(DE-627)ELV025396250 (ELSEVIER)S0924-977X(16)30587-9 |
| title_full |
Genetic Biomarkers For Antipsychotic-Induced Parkinsonism: The Challenge of Replication And Clinical Applicability |
| author_sort |
Lerer, Bernard |
| journal |
Temperature-dependence laws of absorption line shape parameters of the CO |
| journalStr |
Temperature-dependence laws of absorption line shape parameters of the CO |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
100 - Philosophy & psychology 600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
zzz |
| container_start_page |
366 |
| author_browse |
Lerer, Bernard |
| container_volume |
27 |
| physical |
2 |
| class |
150 610 150 DE-600 610 DE-600 530 VZ 33.00 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Lerer, Bernard |
| doi_str_mv |
10.1016/j.euroneuro.2016.09.391 |
| dewey-full |
150 610 530 |
| title_sort |
genetic biomarkers for antipsychotic-induced parkinsonism: the challenge of replication and clinical applicability |
| title_auth |
Genetic Biomarkers For Antipsychotic-Induced Parkinsonism: The Challenge of Replication And Clinical Applicability |
| abstract |
Antipsychotic-induced Parkinsonism (AIP) is an adverse effect that significantly limits the use of first generation antipsychotic drugs (FGAs). Frequency estimates vary from 10-40%. Second generation antipsychotics (SGAs) are associated with lower AIP rates but carry a significant risk of metabolic adverse effects. Thus, personalized treatment with antipsychotics is a key objective in pharmacogenomics. Several studies have sought genetic biomarkers for AIP. Most were retrospective and employed candidate variants in case-control association studies. Some associations have been reported but replication has not been consistent and a level of predictive power appropriate for clinical application has not been demonstrated. A case in point is the association of the functional rs4606 polymorphism in the RGS2 gene with susceptibility to early onset of AIP. This was first reported by our group in a prospective study of Israeli patients with schizophrenia (Greenbaum et al, 2007). The association was replicated in a retrospectively evaluated U.S. sample (Greenbaum et al, 2009) but not by other authors. We also obtained supporting evidence from a transgenic mouse model (Greenbaum et al, 2012a). Subsequently, we presented evidence for association of the intronic SNP, rs12678719, in the ZFPM2 gene with susceptibility to AIP. This was observed in a secondary analysis of CATIE data (Alkelai et al, 2009) and replicated in an independent U.S. case control sample (Greenbaum et al 2012b). Considering the two genetic variants together yielded a positive predictive value of 0.71 and a negative predictive value of 0.68 (odds ratio of 5.13) (Lerer et al, unpublished). To validate these findings we recruited a new sample of 404 Israeli schizophrenia patients on a stable regimen of antipsychotic treatment, of whom 383 had valid phenotypic and genetic data and were included in the data analysis (AIP positive: Simpson Angus Scale (SAS) score>0.3, N=206; AIP resistant, SAS ≤0.13, N=177). Recruitment was constrained to insure equivalent proportions of patients on FGAs and SGAs. Taking into account confounding variables such as age, gender, age at first antipsychotic treatment, ethnicity, antipsychotic drug dose in chlorpromazine units and treatment with anticholinergic medication, the results of this study showed no significant contribution of rs4606 in RGS2 and rs12678719 in ZFPM2 to AIP susceptibility. This was also the case when examining a more extreme phenotype. These findings ill... |
| abstractGer |
Antipsychotic-induced Parkinsonism (AIP) is an adverse effect that significantly limits the use of first generation antipsychotic drugs (FGAs). Frequency estimates vary from 10-40%. Second generation antipsychotics (SGAs) are associated with lower AIP rates but carry a significant risk of metabolic adverse effects. Thus, personalized treatment with antipsychotics is a key objective in pharmacogenomics. Several studies have sought genetic biomarkers for AIP. Most were retrospective and employed candidate variants in case-control association studies. Some associations have been reported but replication has not been consistent and a level of predictive power appropriate for clinical application has not been demonstrated. A case in point is the association of the functional rs4606 polymorphism in the RGS2 gene with susceptibility to early onset of AIP. This was first reported by our group in a prospective study of Israeli patients with schizophrenia (Greenbaum et al, 2007). The association was replicated in a retrospectively evaluated U.S. sample (Greenbaum et al, 2009) but not by other authors. We also obtained supporting evidence from a transgenic mouse model (Greenbaum et al, 2012a). Subsequently, we presented evidence for association of the intronic SNP, rs12678719, in the ZFPM2 gene with susceptibility to AIP. This was observed in a secondary analysis of CATIE data (Alkelai et al, 2009) and replicated in an independent U.S. case control sample (Greenbaum et al 2012b). Considering the two genetic variants together yielded a positive predictive value of 0.71 and a negative predictive value of 0.68 (odds ratio of 5.13) (Lerer et al, unpublished). To validate these findings we recruited a new sample of 404 Israeli schizophrenia patients on a stable regimen of antipsychotic treatment, of whom 383 had valid phenotypic and genetic data and were included in the data analysis (AIP positive: Simpson Angus Scale (SAS) score>0.3, N=206; AIP resistant, SAS ≤0.13, N=177). Recruitment was constrained to insure equivalent proportions of patients on FGAs and SGAs. Taking into account confounding variables such as age, gender, age at first antipsychotic treatment, ethnicity, antipsychotic drug dose in chlorpromazine units and treatment with anticholinergic medication, the results of this study showed no significant contribution of rs4606 in RGS2 and rs12678719 in ZFPM2 to AIP susceptibility. This was also the case when examining a more extreme phenotype. These findings ill... |
| abstract_unstemmed |
Antipsychotic-induced Parkinsonism (AIP) is an adverse effect that significantly limits the use of first generation antipsychotic drugs (FGAs). Frequency estimates vary from 10-40%. Second generation antipsychotics (SGAs) are associated with lower AIP rates but carry a significant risk of metabolic adverse effects. Thus, personalized treatment with antipsychotics is a key objective in pharmacogenomics. Several studies have sought genetic biomarkers for AIP. Most were retrospective and employed candidate variants in case-control association studies. Some associations have been reported but replication has not been consistent and a level of predictive power appropriate for clinical application has not been demonstrated. A case in point is the association of the functional rs4606 polymorphism in the RGS2 gene with susceptibility to early onset of AIP. This was first reported by our group in a prospective study of Israeli patients with schizophrenia (Greenbaum et al, 2007). The association was replicated in a retrospectively evaluated U.S. sample (Greenbaum et al, 2009) but not by other authors. We also obtained supporting evidence from a transgenic mouse model (Greenbaum et al, 2012a). Subsequently, we presented evidence for association of the intronic SNP, rs12678719, in the ZFPM2 gene with susceptibility to AIP. This was observed in a secondary analysis of CATIE data (Alkelai et al, 2009) and replicated in an independent U.S. case control sample (Greenbaum et al 2012b). Considering the two genetic variants together yielded a positive predictive value of 0.71 and a negative predictive value of 0.68 (odds ratio of 5.13) (Lerer et al, unpublished). To validate these findings we recruited a new sample of 404 Israeli schizophrenia patients on a stable regimen of antipsychotic treatment, of whom 383 had valid phenotypic and genetic data and were included in the data analysis (AIP positive: Simpson Angus Scale (SAS) score>0.3, N=206; AIP resistant, SAS ≤0.13, N=177). Recruitment was constrained to insure equivalent proportions of patients on FGAs and SGAs. Taking into account confounding variables such as age, gender, age at first antipsychotic treatment, ethnicity, antipsychotic drug dose in chlorpromazine units and treatment with anticholinergic medication, the results of this study showed no significant contribution of rs4606 in RGS2 and rs12678719 in ZFPM2 to AIP susceptibility. This was also the case when examining a more extreme phenotype. These findings ill... |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
Genetic Biomarkers For Antipsychotic-Induced Parkinsonism: The Challenge of Replication And Clinical Applicability |
| url |
https://doi.org/10.1016/j.euroneuro.2016.09.391 |
| remote_bool |
true |
| author2 |
Greenbaum, Lior |
| author2Str |
Greenbaum, Lior |
| ppnlink |
ELV000200816 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth |
| doi_str |
10.1016/j.euroneuro.2016.09.391 |
| up_date |
2024-07-06T17:27:03.651Z |
| _version_ |
1803851476398768128 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV025396250</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625144710.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.euroneuro.2016.09.391</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017014000005.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV025396250</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0924-977X(16)30587-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">150</subfield><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">150</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">530</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">33.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Lerer, Bernard</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Genetic Biomarkers For Antipsychotic-Induced Parkinsonism: The Challenge of Replication And Clinical Applicability</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">2</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Antipsychotic-induced Parkinsonism (AIP) is an adverse effect that significantly limits the use of first generation antipsychotic drugs (FGAs). Frequency estimates vary from 10-40%. Second generation antipsychotics (SGAs) are associated with lower AIP rates but carry a significant risk of metabolic adverse effects. Thus, personalized treatment with antipsychotics is a key objective in pharmacogenomics. Several studies have sought genetic biomarkers for AIP. Most were retrospective and employed candidate variants in case-control association studies. Some associations have been reported but replication has not been consistent and a level of predictive power appropriate for clinical application has not been demonstrated. A case in point is the association of the functional rs4606 polymorphism in the RGS2 gene with susceptibility to early onset of AIP. This was first reported by our group in a prospective study of Israeli patients with schizophrenia (Greenbaum et al, 2007). The association was replicated in a retrospectively evaluated U.S. sample (Greenbaum et al, 2009) but not by other authors. We also obtained supporting evidence from a transgenic mouse model (Greenbaum et al, 2012a). Subsequently, we presented evidence for association of the intronic SNP, rs12678719, in the ZFPM2 gene with susceptibility to AIP. This was observed in a secondary analysis of CATIE data (Alkelai et al, 2009) and replicated in an independent U.S. case control sample (Greenbaum et al 2012b). Considering the two genetic variants together yielded a positive predictive value of 0.71 and a negative predictive value of 0.68 (odds ratio of 5.13) (Lerer et al, unpublished). To validate these findings we recruited a new sample of 404 Israeli schizophrenia patients on a stable regimen of antipsychotic treatment, of whom 383 had valid phenotypic and genetic data and were included in the data analysis (AIP positive: Simpson Angus Scale (SAS) score>0.3, N=206; AIP resistant, SAS ≤0.13, N=177). Recruitment was constrained to insure equivalent proportions of patients on FGAs and SGAs. Taking into account confounding variables such as age, gender, age at first antipsychotic treatment, ethnicity, antipsychotic drug dose in chlorpromazine units and treatment with anticholinergic medication, the results of this study showed no significant contribution of rs4606 in RGS2 and rs12678719 in ZFPM2 to AIP susceptibility. This was also the case when examining a more extreme phenotype. These findings ill...</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Antipsychotic-induced Parkinsonism (AIP) is an adverse effect that significantly limits the use of first generation antipsychotic drugs (FGAs). Frequency estimates vary from 10-40%. Second generation antipsychotics (SGAs) are associated with lower AIP rates but carry a significant risk of metabolic adverse effects. Thus, personalized treatment with antipsychotics is a key objective in pharmacogenomics. Several studies have sought genetic biomarkers for AIP. Most were retrospective and employed candidate variants in case-control association studies. Some associations have been reported but replication has not been consistent and a level of predictive power appropriate for clinical application has not been demonstrated. A case in point is the association of the functional rs4606 polymorphism in the RGS2 gene with susceptibility to early onset of AIP. This was first reported by our group in a prospective study of Israeli patients with schizophrenia (Greenbaum et al, 2007). The association was replicated in a retrospectively evaluated U.S. sample (Greenbaum et al, 2009) but not by other authors. We also obtained supporting evidence from a transgenic mouse model (Greenbaum et al, 2012a). Subsequently, we presented evidence for association of the intronic SNP, rs12678719, in the ZFPM2 gene with susceptibility to AIP. This was observed in a secondary analysis of CATIE data (Alkelai et al, 2009) and replicated in an independent U.S. case control sample (Greenbaum et al 2012b). Considering the two genetic variants together yielded a positive predictive value of 0.71 and a negative predictive value of 0.68 (odds ratio of 5.13) (Lerer et al, unpublished). To validate these findings we recruited a new sample of 404 Israeli schizophrenia patients on a stable regimen of antipsychotic treatment, of whom 383 had valid phenotypic and genetic data and were included in the data analysis (AIP positive: Simpson Angus Scale (SAS) score>0.3, N=206; AIP resistant, SAS ≤0.13, N=177). Recruitment was constrained to insure equivalent proportions of patients on FGAs and SGAs. Taking into account confounding variables such as age, gender, age at first antipsychotic treatment, ethnicity, antipsychotic drug dose in chlorpromazine units and treatment with anticholinergic medication, the results of this study showed no significant contribution of rs4606 in RGS2 and rs12678719 in ZFPM2 to AIP susceptibility. This was also the case when examining a more extreme phenotype. These findings ill...</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Greenbaum, Lior</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Wilzewski, J.S. ELSEVIER</subfield><subfield code="t">Temperature-dependence laws of absorption line shape parameters of the CO</subfield><subfield code="d">2017</subfield><subfield code="d">ENP : the journal of the European College of Neuropsychopharmacology</subfield><subfield code="g">Amsterdam</subfield><subfield code="w">(DE-627)ELV000200816</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:27</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:366-367</subfield><subfield code="g">extent:2</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.euroneuro.2016.09.391</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">33.00</subfield><subfield code="j">Physik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">27</subfield><subfield code="j">2017</subfield><subfield code="h">366-367</subfield><subfield code="g">2</subfield><subfield code="y">27.2017, S366-, (2 S.)</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">150</subfield></datafield></record></collection>
|
| score |
7.3979883 |